Evidence map›Paper›PMID 28303056›Full record

Trial reportNagoya journal of medical science2017

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.

Chie Aoki, Kunihiro Suzuki, Hisamoto Kuroda, Masaaki Sagara, Masanori Shimizu, Kikuo Kasai, Yoshimasa Aso

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nagoya journal of medical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Japanese Clinical Practice Guideline for Diabetes 2019.Journal of diabetes investigation · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chie AokiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
Kunihiro SuzukiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
Hisamoto KurodaDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan; Green Clinic, Shimotugagun, Japan.
Masaaki SagaraDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
Masanori ShimizuDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
Kikuo KasaiIshibasi General Hospital, Shimotuke, Japan.
Yoshimasa AsoDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
Dokkyo Medical University · JPShioda General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the effects of switching from combination therapy with either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatients with type 2 diabetes mellitus (T2DM) treated with Alo and 47 outpatients with T2DM treated with Pio were switched to Alo-Pio FDCT, and its efficacy and usefulness were evaluated. Significant improvements were observed in hemoglobinA1c (HbA

Indexed as

AgedAlanine TransaminaseBlood GlucoseBody Mass IndexCholesterol, HDLDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemalegamma-GlutamyltransferaseGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedPioglitazonePiperidinesAlanine TransaminasealogliptinBlood GlucoseCholesterol, HDLDipeptidyl-Peptidase IV Inhibitorsgamma-GlutamyltransferaseGlycated HemoglobinHypoglycemic AgentsPioglitazonePiperidinesUracilalogliptindipeptidyl peptidase-4 inhibitorfixed-dose combination therapypioglitazonetype 2 diabetes mellitus

Identifiers

PMID28303056
PMCPMC5346615
OpenAlexW2597792396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.